You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
of hypertension patients do not have their blood pressure under control.1
Hypertension is a major cause of premature
of hypertension patients become non-adherent to their medication within one year.2
Building a successful hypertension program allows you to focus your efforts and drive greater change.
Use our patient-friendly resources to provide an overview of hypertension, its health risks, and why the Symplicity blood pressure procedure might be the right choice.
ANCOVA adjusted; secondary efficacy analysis.
RDN arm reduction from baseline.
World Health Organization. 25 August 2021.
Jung O, Gechter JL. Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Hypertension. 2013;31(4):766-774
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet 2020; Published online March 29, 2020.
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022;399:1401-1410.
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018;391(10137):2346-2355.